Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. August 2004 10:04 ET | Quelle: Biotage AB

Biotage -- Interim report January-June 2004

STOCKHOLM, Sweden, Aug. 12, 2004 (PRIMEZONE) -- Biotage Interim report Contacts: Jeff Bork, President & CEO Tel: +46 734-22 16 60 Mats-Olof Wallin, CFO Tel: +46 705-93 52 73 -- Second...
11. August 2004 02:24 ET | Quelle: Xenova Group PLC

Xenova Group PLC -- Interim Results for the First Half of 2004

SLOUGH, UK, Aug. 11, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today its results for the six months ended 30 June 2004. Year to Date Highlights Development --...
21. Juli 2004 17:00 ET | Quelle: ViroPharma Incorporated

ViroPharma Hosts 'Teach-In' on Cytomegalovirus

EXTON, Pa., July 21, 2004 (PRIMEZONE) -- Highlighting the great need for a well tolerated and effective treatment for cytomegalovirus (CMV), a panel of transplant clinicians and ViroPharma...
21. Juli 2004 01:21 ET | Quelle: F. Hoffmann-La Roche AG

First Half of 2004: Roche Posts Market Share Gains on Double-Digit Sales Growth; Earnings Performance Improves Significantly

BASEL, Switzerland, July 21, 2004 (PRIMEZONE) -- Roche Group: -- Sales* up 14% in local currencies to 14.6 billion Swiss francs -- Operating profit** climbs 33% in local currencies to 3.7...
20. Juli 2004 06:20 ET | Quelle: Biotage AB

Extraordinary general meeting in Biotage -- Authorization to the Board

STOCKHOLM, Sweden, July 20, 2004 (PRIMEZONE) -- The Extraordinary General Meeting of Biotage has today resolved to authorize the Board of Directors to issue new shares not exceeding in total...
14. Juli 2004 03:59 ET | Quelle: Xenova Group PLC

Successful Results from Second Clinical Trial of Anti-Smoking Vaccine, TA-NIC

SLOUGH, U.K., July 14, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today initial results from the second clinical trial of TA-NIC, the Company's therapeutic vaccine being...
07. Juli 2004 02:28 ET | Quelle: Xenova Group PLC

TransMID -- First Patient Treated in Pivotal Phase III GBM Trial

SLOUGH, U.K., July 7, 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today that patient dosing has begun in the Phase III clinical trial of TransMID(TM) for the treatment of...
05. Juli 2004 02:00 ET | Quelle: Novartis Pharma AG

Novartis Institute for Tropical Diseases opens in Singapore's state-of-the-art Biopolis research facility

Novartis Institute for Tropical Diseases opens in Singapore's state-of-the-art Biopolis research facility Unique non-profit initiative in drug discovery for neglected diseasesBasel, Switzerland and...
05. Juli 2004 02:00 ET | Quelle: Novartis Pharma AG

Das Novartis Institute for Tropical Diseases neu in Singapurs hochmodernem Forschungspark Biopolis

Einzigartige nicht gewinnorientierte Initiative zur Entdeckung von Medikamenten gegen vernachlässigte KrankheitenBasel, Schweiz und Singapur, 5. Juli 2004 - Novartis gab heute die offizielle Eröffnung...
30. Juni 2004 12:29 ET | Quelle: Biotage AB

Notice of Extraordinary General Meeting of Biotage AB

UPPSALA, Sweden, June 30, 2004 (PRIMEZONE) -- Shareholders in Biotage AB, Reg. No. 556539-3138, are hereby invited to attend the Extraordinary General Meeting, to be held on Tuesday, July 20, 2004,...

Vorherige Seite